Please use this identifier to cite or link to this item:
Title: Investigational cannabinoids in seizure disorders, what have we learned thus far?
Authors: Ruzic Zecevic, Dejana
Folic, Marko
Tantoush Z.
Radovanovic, Milan
Babic, Goran
Jankovic, Slobodan
Issue Date: 2018
Abstract: © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction:The anticonvulsant activity of cannabinoids attracted much attention in the last decade. Cannabinoids that are currently investigated with the intention of making them drugs for the treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin, and Δ9-tetrahydrocannabinolic acid. Areas covered:In this review, the authors look at the results of preclinical and clinical studies with investigational cannabinoids. Relevant literature was searched for in MEDLINE, SCOPUS, EBSCO, GOOGLE SCHOLAR, and SCINDEX databases. Expert opinion: Preclinical studies confirmed anticonvulsant activity of cannabidiol and cannabidivarin in a variety of epilepsy models. While the results of clinical trials with cannabidivarin are still awaited, cannabidiol showed clear therapeutic benefit and good safety in patients with therapy-resistant seizures associated with Dravet syndrome and in patients with Lennox–Gastaut syndrome who have drop seizures. However, the full therapeutic potential of cannabinoids in treatment-resistant epilepsy needs to be investigated in the near future.
Type: review
DOI: 10.1080/13543784.2018.1482275
ISSN: 1354-3784
SCOPUS: 2-s2.0-85050223322
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
  Restricted Access
29.86 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.